Acurx Pharmaceuticals (NASDAQ:ACXP) Stock Price Down 2.3% – What’s Next?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shares were down 2.3% during trading on Monday . The stock traded as low as $2.14 and last traded at $2.14. Approximately 17,641 shares changed hands during mid-day trading, a decline of 59% from the average daily volume of 42,882 shares. The stock had previously closed at $2.19.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Wall Street Zen upgraded Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Stock Performance

The stock has a 50 day moving average price of $2.99 and a 200 day moving average price of $4.36. The company has a market cap of $5.46 million, a P/E ratio of -0.25 and a beta of -1.22.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its earnings results on Wednesday, November 12th. The company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.38. As a group, equities research analysts predict that Acurx Pharmaceuticals, Inc. will post -0.89 earnings per share for the current year.

Institutional Trading of Acurx Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACXP. O Brien Greene & Co. Inc bought a new stake in Acurx Pharmaceuticals during the second quarter worth approximately $31,000. Geode Capital Management LLC acquired a new stake in shares of Acurx Pharmaceuticals during the 4th quarter valued at $31,000. Finally, Armistice Capital LLC acquired a new stake in shares of Acurx Pharmaceuticals during the 2nd quarter valued at $551,000. 11.53% of the stock is owned by institutional investors and hedge funds.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).